Target type: biologicalprocess
Any apoptotic process in a melanocyte, the main structural component of the epidermis. [GOC:ic, GOC:TermGenie, PMID:20530876]
Melanocyte apoptosis is a complex, tightly regulated process that involves a series of biochemical and molecular events leading to the programmed death of melanocytes. These events are triggered by a variety of factors, including UV radiation, oxidative stress, and cytotoxic agents.
The process begins with the activation of intracellular signaling pathways, such as the caspase cascade and the mitochondrial apoptotic pathway. Activation of these pathways leads to the breakdown of cellular components, including DNA, proteins, and organelles.
Specifically, the caspase cascade involves a series of proteases that cleave specific proteins, leading to the dismantling of the cell. This process is initiated by the activation of initiator caspases, such as caspase-8 and caspase-9, which then activate effector caspases, such as caspase-3 and caspase-7. These effector caspases cleave a variety of cellular substrates, leading to the characteristic features of apoptosis, such as DNA fragmentation, cell shrinkage, and the formation of apoptotic bodies.
The mitochondrial apoptotic pathway involves the release of cytochrome c from the mitochondria into the cytoplasm. Cytochrome c then binds to the apoptotic protease activating factor 1 (Apaf-1), which activates caspase-9.
These events lead to the morphological changes characteristic of apoptosis, including cell shrinkage, nuclear fragmentation, and the formation of apoptotic bodies. These bodies are then engulfed and degraded by phagocytes, preventing the release of cellular contents into the surrounding tissues.
Melanocyte apoptosis plays a crucial role in maintaining skin homeostasis and preventing the development of skin cancer. However, dysregulation of the apoptotic process can lead to skin disorders such as vitiligo and melanoma. Understanding the molecular mechanisms underlying melanocyte apoptosis is therefore essential for developing effective therapeutic strategies for these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Prolyl endopeptidase FAP | A prolyl endopeptidase FAP that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q12884] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
n-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide | N-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide: fluorogenic substrate for post-proline cleaving enzyme | ||
sitagliptin | sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity. | triazolopyrazine; trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic |
vildagliptin | amino acid amide | ||
talabostat | talabostat: an antineoplastic agent; structure in first source | ||
linagliptin | linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes. Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS. | aminopiperidine; quinazolines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent |
kyp 2047 | |||
bms 477118 | adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent | |
alogliptin | alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes. alogliptin: structure in first source | nitrile; piperidines; primary amino compound; pyrimidines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent |
gosogliptin | amino acid amide | ||
anagliptin | anagliptin: anagliptin hydrochloride salt is the active compound | amino acid amide | |
mk-3102 | pyrrolopyrazole |